CSC marker analysis and Nanostic analysis in patient tissues

To further investigate CSCs/ESCs, KI will explore CSC markers in endometrial /endometriotic samples in a large number (n=50) of endometriosis patients to identify endometriosis patients with high risk for EAOEC and develop a prophylactic strategy. This study will be assisted by partners CONICET and WWU. Proliferative phase endometrial and endometriotic samples will be collected at the time of surgery from women undergoing surgery for endometriosis. The expression levels of CSC markers will be quantified by real time PCR and protein quantification setup Wes.This work will be complemented by a studying the whole transcriptome (mRNA, miRNA) and by epigenetic profiling of endometrial /endometriotic samples from women with endometriosis expressing cancer stem cells to understand the molecular mechanism and find new markers to develop prophylactic measures. For this, next generation RNA sequencing with illumina platform available at KI will be used. Differential expression between the groups will be compared using bioinformatics platform, Ingenuity Pathway Analysis (IPA) at KI. This study will give knowledge on functional and non-functional genes and its association with signalling pathways, which have carcinogenic linkage. Genome wide scanning for epigenetic profile in endometrium and endometrioma will be studied using high throughput meDI . These results will be analysed together with transcriptome data using IPA. Nanostic atomic force microscopy to characterize enSC with the expression of CSC to screen endometrium of high risk patients for EAOEC by partner KI will be done with partner Serend-IP.